Healthcare
Angiex, Inc. – SUCCESS PAGE – March 20, 2025
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
A biotech company developing a platform of novel antibodies and ADCs to treat life-threatening cancers including leukemia and lymphoma
A biotech company developing a platform of novel antibodies and ADCs to treat life-threatening cancers including leukemia and lymphoma
ZYUS Life Sciences (CVE: ZYUS) has developed a new compound that treats chronic pain effectively without opioids.
ZYUS Life Sciences (CVE: ZYUS) has developed a new compound that treats chronic pain effectively without opioids.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Alzheon is a clinical-stage biopharma company with a first-in-class oral treatment targeting the root cause of Alzheimer’s disease.
Alzheon is a clinical-stage biopharma company with a first-in-class oral treatment targeting the root cause of Alzheimer’s disease.
1460 Broadway
New York, NY 10036
(917) 747-6198
© Copyright 2025 FORCE Family Office
